BASAGLAR® (insulin glargine injection) 100 units/mL
Pharmacokinetic (PK) profile
BASAGLAR and Lantus (US-approved) PD properties over a 24-hour period3
A phase 1 randomized, double-blind, single-dose, 2-treatment, 4-period, crossover, replicate treatment, euglycemic clamp study with 91 healthy subjects evaluated the PK and pharmacodynamic (PD) profiles for BASAGLAR and Lantus (US-approved) given subcutaneously as single, 0.5 unit/kg doses.3
PK results: Based on statistical comparisons of area under the plasma concentration–time curve from 0 to 24 hours (AUC0-24) and maximum plasma concentration (Cmax) of BASAGLAR and Lantus (US-approved), the ratios of least squares (LS) geometric means were 0.90 and 0.92 for AUC0-24 and Cmax, respectively, with 90% confidence intervals (CIs) for the ratios contained within the prespecified interval of 0.80 to 1.25.3
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.